Active	Status	Sponsor type	Region	Phase	Filter
2 Active 1 Inactive 3 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other Show only owner-sponsored trials	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
lesigercept (GI-301) / Yuhan Corp
NCT05564221: A Multiple Ascending Dose, Phase 1b Study of YH35324 in Atopic Healthy Subjects or Subjects With Allergic Diseases	Completed	1	46	RoW	YH35324, Placebo, Omalizumab, Xolair® prefilled syringe 150 for injection	Yuhan Corporation	Atopic Healthy Subjects, Adult Subjects With Allergic Diseases	11/24	11/24
NCT05960708: A Single Dose, Phase 1 Study of YH35324 in Patients with Various Allergic Diseases	Completed	1	30	RoW	YH35324, Omalizumab, Xolair® prefilled syringe 150 for injection, Placebo	Yuhan Corporation	Allergic Disease, Chronic Spontaneous Urticaria, Chronic Inducible Urticaria, Cold Urticaria	09/24	09/24